Puma Biotechnology/$PBYI
1D1W1MYTD1Y5YMAX
Capital at risk
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Ticker
- $PBYI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 179
- Headquarters
- Los Angeles, United States
- Website
- www.pumabiotechnology.com
PBYI Metrics
BasicAdvanced
$508M
19.54
$0.50
1.23
-
Price and volume
Market cap
$508M
Beta
1.23
52-week high
$10.10
52-week low
$4.58
Average daily volume
313K
Financial strength
Current ratio
2.912
Quick ratio
2.568
Long term debt to equity
0.032
Total debt to equity
0.035
Interest coverage (TTM)
8.65%
Profitability
EBITDA (TTM)
40.115
Gross margin (TTM)
74.83%
Net profit margin (TTM)
11.55%
Operating margin (TTM)
13.17%
Effective tax rate (TTM)
14.28%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
9.82%
Return on equity (TTM)
21.99%
Valuation
Price to earnings (TTM)
19.541
Price to revenue (TTM)
2.154
Price to book
3.63
Price to tangible book (TTM)
4.93
Price to free cash flow (TTM)
12.105
Free cash flow yield (TTM)
8.26%
Free cash flow per share (TTM)
0.813
Growth
Revenue change (TTM)
-2.86%
Earnings per share change (TTM)
-48.22%
3-year revenue growth (CAGR)
0.16%
3-year earnings per share growth (CAGR)
101.58%
10-year earnings per share growth (CAGR)
-24.17%
What the Analysts think about PBYI
Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.
Analyst projections of the future price of Puma Biotechnology stock.
Bulls say / Bears say
NERLYNX demand is showing renewed momentum. Q2 net product revenue rose to $53.6 million from $49.2 million a year earlier, and Puma raised its 2026 product-revenue guidance to $205–209 million. (Puma Biotechnology, The Motley Fool)
Puma has reached a debt-free position while remaining profitable, giving it more flexibility to fund development internally. Management reported $93.9 million of cash and securities at the end of Q2 and said it believes current projections can support potential Phase III work, potentially without near-term equity dilution. (StockAnalysis, TradingView News)
Alisertib is gaining a clearer biomarker-led development strategy rather than being tested indiscriminately across all patients. Puma has now started ALISCA-Lung2 in combination with paclitaxel for advanced small-cell lung cancer, creating a near-term clinical catalyst and a potential second oncology franchise. (Puma Biotechnology, The Motley Fool)
Puma remains heavily dependent on NERLYNX, because it provides all product revenue. New prescriptions fell about 6% quarter on quarter in Q2 even as total prescriptions and bottle volumes rose, which suggests that underlying new-patient demand is not yet consistently accelerating. (Simply Wall St, Puma Biotechnology)
International royalty income faces pressure from generic NERLYNX competition in China. Management cut its 2026 royalty guidance and said the royalty rate could decline if Chinese generic market share reaches a specified threshold, potentially from late 2026 or 2027. (TradingView News, Puma Biotechnology)
Alisertib is still an unapproved Phase II programme, so its value depends on clinical data that has not yet proved it can support registration. The current plan calls for further breast-cancer data in late 2026 and additional lung-cancer data in 2027, leaving meaningful trial and execution risk. (The Motley Fool, Puma Biotechnology)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
PBYI Financial Performance
Revenues and expenses
PBYI Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBYI News
AllArticlesVideos
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Business Wire2 weeks ago
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Business Wire3 weeks ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Funds containing PBYI
AllUSDGBPEUR
Fund name | Fund size | $PBYI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.